Need Help?

Multi-region RNA sequencing of tumour regions and tumour-adjacent normal lung tissue

TRACERx (TRAcking Cancer Evolution through therapy (Rx)) is a prospective cohort study designed to investigate intratumor heterogeneity (ITH) in relation to clinical outcome, and to determine the clonal nature of driver events and evolutionary processes in early stage non-small cell lung cancer (NSCLC).

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001009862 Illumina HiSeq 4000 1051
Publications Citations
Evolutionary characterization of lung adenocarcinoma morphology in TRACERx.
Nat Med 29: 2023 833-845
19
Genomic-transcriptomic evolution in lung cancer and metastasis.
Nature 616: 2023 543-552
52
Antibodies against endogenous retroviruses promote lung cancer immunotherapy.
Nature 616: 2023 563-573
70
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA.
Nature 616: 2023 553-562
68
Quantifying the impact of immunotherapy on RNA dynamics in cancer.
J Immunother Cancer 11: 2023 e007870
0
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.
Nat Genet 56: 2024 60-73
19
Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer.
Cancer Discov 14: 2024 1018-1047
10
Cancer cell - Fibroblast crosstalk via HB-EGF, EGFR, and MAPK signaling promotes the expression of macrophage chemo-attractants in squamous cell carcinoma.
iScience 27: 2024 110635
0